These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9054631)

  • 21. DNA binding activity of the mammalian translation elongation complex: recognition of chromium- and transplatin-damaged DNA.
    Wang JF; Engelsberg BN; Johnson SW; Witmer C; Merrick WC; Rozmiarek H; Billings PC
    Arch Toxicol; 1997; 71(7):450-4. PubMed ID: 9209691
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytotoxicity, apoptosis, and in vitro DNA damage induced by potassium chromate.
    Flores A; Pérez JM
    Toxicol Appl Pharmacol; 1999 Nov; 161(1):75-81. PubMed ID: 10558925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
    Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
    Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carcinogenic chromium(VI)-induced protein oxidation and lipid peroxidation: implications in DNA-protein crosslinking.
    Mattagajasingh SN; Misra BR; Misra HP
    J Appl Toxicol; 2008 Nov; 28(8):987-97. PubMed ID: 18615841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
    Vaisman A; Lim SE; Patrick SM; Copeland WC; Hinkle DC; Turchi JJ; Chaney SG
    Biochemistry; 1999 Aug; 38(34):11026-39. PubMed ID: 10460158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of chromium(V) in the mechanism of chromate-induced oxidative DNA damage and cancer.
    Sugden KD; Stearns DM
    J Environ Pathol Toxicol Oncol; 2000; 19(3):215-30. PubMed ID: 10983888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cisplatin-DNA binding specificity of calf high-mobility group 1 protein.
    Turchi JJ; Li M; Henkels KM
    Biochemistry; 1996 Mar; 35(9):2992-3000. PubMed ID: 8608137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxia impedes the formation of chromium DNA-adducts in a cell-free system.
    O'Brien TJ; Mandel HG; Sugden KD; Komarov AM; Patierno SR
    Biochem Pharmacol; 2005 Dec; 70(12):1814-22. PubMed ID: 16242673
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms.
    Marples B; Adomat H; Billings PC; Farrell NP; Koch CJ; Skov KA
    Anticancer Drug Des; 1994 Oct; 9(5):389-99. PubMed ID: 7945723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carcinogenic Cr(VI) and the nutritional supplement Cr(III) induce DNA deletions in yeast and mice.
    Kirpnick-Sobol Z; Reliene R; Schiestl RH
    Cancer Res; 2006 Apr; 66(7):3480-4. PubMed ID: 16585171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromium-induced production of reactive oxygen species, DNA single-strand breaks, nitric oxide production, and lactate dehydrogenase leakage in J774A.1 cell cultures.
    Hassoun EA; Stohs SJ
    J Biochem Toxicol; 1995 Dec; 10(6):315-21. PubMed ID: 8934634
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preferential binding of high mobility group 1 protein to UV-damaged DNA. Role of the COOH-terminal domain.
    Pasheva EA; Pashev IG; Favre A
    J Biol Chem; 1998 Sep; 273(38):24730-6. PubMed ID: 9733773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genotoxicity and mutagenicity of chromium(VI)/ascorbate-generated DNA adducts in human and bacterial cells.
    Quievryn G; Peterson E; Messer J; Zhitkovich A
    Biochemistry; 2003 Feb; 42(4):1062-70. PubMed ID: 12549927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two pathways for chromium(VI)-induced DNA damage in 14 day chick embryos: Cr-DNA binding in liver and 8-oxo-2'-deoxyguanosine in red blood cells.
    Misra M; Alcedo JA; Wetterhahn KE
    Carcinogenesis; 1994 Dec; 15(12):2911-7. PubMed ID: 8001255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein.
    Imamura T; Izumi H; Nagatani G; Ise T; Nomoto M; Iwamoto Y; Kohno K
    J Biol Chem; 2001 Mar; 276(10):7534-40. PubMed ID: 11106654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural and kinetic studies of a cisplatin-modified DNA icosamer binding to HMG1 domain B.
    Jamieson ER; Jacobson MP; Barnes CM; Chow CS; Lippard SJ
    J Biol Chem; 1999 Apr; 274(18):12346-54. PubMed ID: 10212205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromium(III) triggers the DNA-damaged checkpoint of the cell cycle and induces a functional increase of 4E-BP.
    Le Bouffant R; Mulner-Lorillon O; Morales J; Cormier P; Bellé R
    Chem Res Toxicol; 2008 Feb; 21(2):542-9. PubMed ID: 18197632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin.
    Zlatanova J; Yaneva J; Leuba SH
    FASEB J; 1998 Jul; 12(10):791-9. PubMed ID: 9657519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formation of the amino acid-DNA complexes by hexavalent and trivalent chromium in vitro: importance of trivalent chromium and the phosphate group.
    Zhitkovich A; Voitkun V; Costa M
    Biochemistry; 1996 Jun; 35(22):7275-82. PubMed ID: 8679557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Molecular effects of chromium compound activity].
    Woźniak K
    Postepy Hig Med Dosw; 1996; 50(4):383-94. PubMed ID: 9019747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.